Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $855.20 MXN
Change Today 0.00 / 0.00%
Volume 0.0
SNYN On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 4:09 PM 07/24/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Open
$855.20
Previous Close
$855.20
Day High
$855.20
Day Low
$855.20
52 Week High
07/20/15 - $855.20
52 Week Low
11/4/14 - $615.18
Market Cap
2.2T
Average Volume 10 Days
306.0
EPS TTM
--
Shares Outstanding
2.6B
EX-Date
05/6/15
P/E TM
--
Dividend
$1.50
Dividend Yield
2.89%
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi-adr (SNYN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi-adr (SNYN) Key Developments

Sanofi Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reports Impairment Charges for the Second Quarter Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Sanofi reported consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of EUR 9,378 million against EUR 8,075 million a year ago. Operating income was EUR 1,995 million against EUR 1,246 million a year ago. Net income attributable to equity holders of the company was EUR 1,302 million or EUR 1.00 per share against EUR 777 million or EUR 0.59 per share a year ago. Income before tax and associates and joint ventures was EUR 1,883 million against EUR 1,152 million a year ago. For the six months, the company reported net sales of EUR 18,188 million against EUR 15,917 million a year ago. Operating income was EUR 3,398 million against EUR 2,674 million a year ago. Income before tax and associates and joint ventures was EUR 3,189 million against EUR 2,539 million a year ago. Net income attributable to equity holders of the company was EUR 2,325 million or EUR 1.78 per share against EUR 1,861 million or EUR 1.41 per share a year ago. Acquisitions of property, plant and equipment and software were EUR 667 million against EUR 529 million for the same period last year. Free cash flow was EUR 3,084 million against EUR 2,390 million a year ago. Net debt was increased from EUR 7,171 million at December 31, 2014 to EUR 9,726 million at June 30, 2015 (amount net of EUR 4,701 million cash and cash equivalents) and included the translation impact of the debt, which represented EUR 391 million, mainly related to the debt held in U.S. dollars. For the quarter, the company reported impairment of intangible assets of EUR 1 million against EUR 71 million a year ago. The company expected 2015 business EPS to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events In addition, the positive currency impact on 2015 full-year business EPS is estimated to be approximately +10%, under the assumption that exchange rates remain stable in the following two quarters at the average rates of June 2015.

Sanofi's First LixiLan Phase III Study Met Primary Endpoint

Sanofi announced that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. Overall, the fixed-ratio combination had a safety profile reflecting those of lixisenatide and insulin glargine 100 units/mL. The Phase III LixiLan clinical development program began in first quarter of 2014 and consists of the LixiLan-O and LixiLan-L trials. LixiLan-O investigated the efficacy and safety of a once-daily single injection of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide versus treatment with either lixisenatide or insulin glargine 100 units/mL over a 30 week period in 1,170 patients whose type 2 diabetes was not adequately controlled on metformin alone or on metformin combined with a second oral anti-diabetic agent. Treatment with metformin was continued for all participants throughout the study. Full results will be communicated in an appropriate scientific forum. The ongoing LixiLan-L study investigates the efficacy and safety of a once-daily single injection of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide versus treatment with insulin glargine 100 units/mL over a 30-week period in 736 patients whose type 2 diabetes was not adequately controlled at screening on a basal insulin with or without oral anti-diabetic drugs. Only metformin, if taken, was continued throughout the study. The study will be completed in third quarter of 2015. Following an analysis of results from both Phase III studies, LixiLan-O and LixiLan-L, Sanofi will determine the next steps in the regulatory process. Currently, regulatory submissions are planned for fourth quarter of 2015 in the United States and first quarter of 2016 in the European Union.

Regeneron Pharmaceuticals, Inc. and Sanofi Launch Major New Immuno-Oncology Collaboration

Regeneron Pharmaceuticals, Inc. and Sanofi entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs. Sanofi will make an upfront payment to Regeneron of $640 million, and the companies will invest $1 billion for discovery through proof of concept (POC) development (usually a Phase 2a study) of monotherapy and novel combinations of immuno-oncology antibody candidates to be funded 25% by Regeneron ($250 million) and 75% by Sanofi ($750 million). The companies have also committed to equally fund an additional $650 million (or $325 million per company) for development of REGN2810, a PD-1 inhibitor. In addition, Sanofi will pay Regeneron a one-time milestone of $375 million in the event that sales of a PD-1 product and any other collaboration antibody sold for use in combination with a PD-1 product exceed, in the aggregate, $2 billion in any consecutive 12-month period. Finally, the two companies have agreed to re-allocate $75 million (over three years) for immuno-oncology antibodies from Sanofi's $160 million annual contribution to their existing antibody collaboration, which otherwise continues as announced in November 2009. Beyond the committed funding, additional funding will be allocated as programs enter post-POC development. The new agreement covers both monoclonal antibodies and new bi-specific antibodies, a variation of standard antibody therapeutics in which two distinct targets within the body can be bound by the same molecule, usually the cancer cell and an immune cell. Regeneron has developed a novel and flexible manufacturing platform that enables efficient production of bi-specific antibodies that are otherwise similar to natural antibodies. Beyond PD-1, other programs in preclinical development include antibodies to lymphocyte-activation gene 3 (LAG3), glucocorticoid-induced tumor-necrosis-factor-receptor-related protein (GITR) and a programmed death ligand (PD-L1) inhibitor. Finally, the collaboration is advancing bi-specific antibodies that target hematologic and solid cancers, either as monotherapies or in combination regimens with other immune modulating treatments. The framework of the new immuno-oncology collaboration is as follows: Regeneron will be responsible for discovery, antibody generation and development through POC, at which time Sanofi will have the ability to opt-in to further development and commercialization. In the existing antibody collaboration, Sanofi has the opportunity to opt-in at the time of an Investigational New Drug application (IND); The companies will alternate serving as the lead development and commercialization organization after Sanofi opts-in to an antibody program; For programs where Regeneron is the lead, including REGN2810, Regeneron will serve as the U.S. commercial lead, including recording U.S. sales, and the companies will equally fund post-POC development. Sanofi will record sales and serve as the commercial lead for all countries outside the U.S.; Sanofi will retain the right to co-promote in the U.S. and Regeneron will retain the right to co-promote outside the U.S. For programs where Sanofi is the lead, Sanofi will serve as the U.S. commercial lead and fund 100% of post-POC development, with Regeneron reimbursing up to 50% of such costs through the IO collaboration development balance, which represents the amount of development funding that Regeneron is obligated to repay out of its share of profits as described below. Sanofi will record sales and serve as the commercial lead for all countries outside the U.S. Regeneron will retain the right to co-promote in the U.S. and outside the U.S. Sanofi and Regeneron will share equally in worldwide profits from sale of collaboration immuno-oncology antibodies; As in the existing antibody agreement, Regeneron will repay the immuno-oncology collaboration development balance from its share of overall profits of the immuno-oncology antibodies, in an annual amount equal to 10% of the Regeneron share of profits. The exclusive collaboration to discover and develop potential monotherapy or novel combination immuno-oncology antibody candidates through POC will last five years with an ability to extend the collaboration for selected ongoing programs for an additional three years. The agreement does not include Chimeric Antigen Receptors. Additional terms, including potential therapeutic targets or mechanisms, were not disclosed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $855.20 MXN 0.00

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $70.16 USD -0.61
Amgen Inc $171.69 USD +0.22
Bayer AG €133.88 EUR -1.75
Gilead Sciences Inc $117.90 USD +2.19
Novo Nordisk A/S kr397.20 DKK -2.80
View Industry Companies
 

Industry Analysis

SNYN

Industry Average

Valuation SNYN Industry Range
Price/Earnings 30.8x
Price/Sales 3.7x
Price/Book 2.3x
Price/Cash Flow 19.5x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.